首页> 外文期刊>Biotechnology Progress >Expansion of Human Neural Precursor Cells in Large-Scale Bioreactors for the Treatment of Neurodegenerative Disorders
【24h】

Expansion of Human Neural Precursor Cells in Large-Scale Bioreactors for the Treatment of Neurodegenerative Disorders

机译:大型生物反应器中人类神经前体细胞的扩增,用于治疗神经退行性疾病

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The transplantation of in vitro expanded human neural precursor cells(hNPCs)represents a potential new treatment alternative for individuals suffering from incurable neurodegenerative disorders such as Parkinson's disease(PD)and Huntington's disease(HD).However,in order for cell restorative therapy to have widespread therapeutic significance,it will be necessary to generate unlimited quantities of clinical grade hNPCs in a standardized method.We report here that we have developed a serum-free medium and scale-up protocols that allow for the generation of clinical quantities of human telencephalon-derived hNPCs in 500-mL computer-controlled suspension bioreactors.The average KNPC aggregate diameter in the bioreactors was maintained below a target value of 500 mu m by controlling the liquid shear field.The human cells,which were inoculated at 10~5 cells/mL,exhibited a doubling time of 84 h,underwent a 36-fold expansion over the course of 18 days,and maintained an average viability of over 90%.The bioreactor-derived hNPCs retained their nestin expression following expansion and were able to differentiate into glial and neuronal pheno-types under defined conditions.It has also been demonstrated that these hNPCs differentiated to a GABAergic phenotype that has recently been shown to be able to restore functional behavior in rat models of HD and neuropathic pain(Mukhida,K.et al.Stem Cells 2007;DOI 10.1634/stemcells.2007-0326).This study demonstrates that clinical quantities of hNPCs can be successfully and reproducibly generated under standardized conditions in computer-controlled suspension bioreactors.
机译:体外扩增的人类神经前体细胞(hNPC)的移植为患有不可治愈的神经退行性疾病(如帕金森氏病(PD)和亨廷顿氏病(HD))的患者提供了一种潜在的新治疗方法。具有广泛的治疗意义,因此有必要采用标准化方法生成无限数量的临床级hNPC。我们在此报告,我们已经开发出了无血清培养基和放大方案,可以生成临床量的人类端脑神经元。在500 mL计算机控制的悬浮生物反应器中获得hNPCs。通过控制液体剪切场将生物反应器中KNPC的平均聚集直径保持在目标值500μm以下。将人类细胞接种到10〜5个细胞/毫升,倍增时间为84小时,在18天的过程中进行了36倍的扩展,并保持了平均90%的生物反应器衍生的hNPCs在扩增后仍保持其巢蛋白表达,并能够在特定条件下分化为神经胶质和神经元表型。还证明了这些hNPCs已分化为GABA能表型。能够在HD和神经性疼痛的大鼠模型中恢复功能行为(Mukhida,K.et al.Stem Cells 2007; DOI 10.1634 / stemcells.2007-0326)。这项研究表明,可以成功且可复制地产生hNPC的临床量。在计算机控制的悬浮生物反应器的标准条件下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号